| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 14.3 | 11.6 |
| Profit before tax | -38.9 | -44.5 |
| Net income | -39.3 | -35.5 |
| EPS (diluted, $ a share) | $-0.25 | $-0.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +23.4% |
|---|---|
| Operating margin | -235.7% |
10-Q filed with the SEC, NASDAQ: CHRS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Coherus Oncology, Inc.: key numbers
- Share price
- $0.4785Close, Nov 17
- Market cap
- $73.9M
- Shares outstanding
- 154.54MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Coherus Oncology, Inc.
All →Coherus Oncology Financial Results
Coherus Oncology reported Q3 2026 financial results, highlighted by $14.0 million in LOQTORZI net revenue. The company also announced a strategic prioritization plan focusing on tagmokitug for esophageal cancer and a 30% headcount reduction to lower quarterly cash burn.
- Term
- Q3 2026
“The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization”
Dennis M. Lanfear, Chief Executive Officer
“The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model”
Bryan McMichael, Chief Financial Officer
Coherus Oncology Clinical Trial Data
Coherus Oncology announced interim clinical data from its TREGCHECK program evaluating tagmokitug, a cytolytic CCR8 antibody, in combination with toripalimab for esophageal squamous cell carcinoma (ESCC). The study reported a 75% confirmed overall response rate (cORR) in first-line ESCC patients irrespective of PD-L1 status, which increased to 89% following the data cutoff. The results provide clinical proof-of-concept for tagmokitug and support the expansion of enrollment in both first-line and second-line ESCC cohorts.